These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10944598)

  • 21. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
    Faivre S; Raymond E; Boige V; Gatineau M; Buthaut X; Rixe O; Bernareggi A; Camboni G; Armand JP
    Clin Cancer Res; 2001 Jan; 7(1):43-50. PubMed ID: 11205916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
    Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
    Dittrich C; Dumez H; Calvert H; Hanauske A; Faber M; Wanders J; Yule M; Ravic M; Fumoleau P
    Clin Cancer Res; 2003 Nov; 9(14):5195-204. PubMed ID: 14613999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
    Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Observations with an S-adenosylmethionine decarboxylase inhibitor in rats with prostatic adenocarcinoma.
    Seiler N; Delcros JG; Cipolla B; Chamaillard L; Havouis R; Quemener V; Moulinoux JP
    Arzneimittelforschung; 1996 Mar; 46(3):311-5. PubMed ID: 8901156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.
    Soepenberg O; de Jonge MJ; Sparreboom A; de Bruin P; Eskens FA; de Heus G; Wanders J; Cheverton P; Ducharme MP; Verweij J
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):703-11. PubMed ID: 15701859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
    Mita AC; Denis LJ; Rowinsky EK; Debono JS; Goetz AD; Ochoa L; Forouzesh B; Beeram M; Patnaik A; Molpus K; Semiond D; Besenval M; Tolcher AW
    Clin Cancer Res; 2009 Jan; 15(2):723-30. PubMed ID: 19147780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers.
    Bhargava P; Marshall JL; Dahut W; Rizvi N; Trocky N; Williams JI; Hait H; Song S; Holroyd KJ; Hawkins MJ
    Clin Cancer Res; 2001 Dec; 7(12):3912-9. PubMed ID: 11751482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients.
    Grem JL; Harold N; Keith B; Chen AP; Kao V; Takimoto CH; Hamilton JM; Pang J; Pace M; Jasser GB; Quinn MG; Monahan BP
    Clin Cancer Res; 2002 Jul; 8(7):2149-56. PubMed ID: 12114415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
    Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK
    Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
    Lockhart AC; Bukowski R; Rothenberg ML; Wang KK; Cooper W; Grover J; Appleman L; Mayer PR; Shapiro M; Zhu AX
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):203-9. PubMed ID: 17091249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor.
    Plummer R; Rees C; Hughes A; Beale P; Highley M; Trigo J; Gokul S; Judson I; Calvert H; Jackman A; Mitchell F; Smith R; Douglass E
    Clin Cancer Res; 2003 Apr; 9(4):1313-22. PubMed ID: 12684399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors.
    de Jonge MJ; van der Gaast A; Planting AS; van Doorn L; Lems A; Boot I; Wanders J; Satomi M; Verweij J
    Clin Cancer Res; 2005 May; 11(10):3806-13. PubMed ID: 15897580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors.
    Salazar R; Bissett D; Twelves C; Breimer L; DeMario M; Campbell S; Zhi J; Ritland S; Cassidy J
    Clin Cancer Res; 2004 Jul; 10(13):4374-82. PubMed ID: 15240525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.
    Advani R; Fisher GA; Lum BL; Jambalos C; Cho CD; Cohen M; Gollerkeri A; Sikic BI
    Clin Cancer Res; 2003 Nov; 9(14):5187-94. PubMed ID: 14613998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
    Dragovich T; Mendelson D; Kurtin S; Richardson K; Von Hoff D; Hoos A
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):759-64. PubMed ID: 16847673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
    Ebbinghaus S; Rubin E; Hersh E; Cranmer LD; Bonate PL; Fram RJ; Jekunen A; Weitman S; Hammond LA
    Clin Cancer Res; 2005 Nov; 11(21):7807-16. PubMed ID: 16278403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer.
    Horti J; Juhasz E; Monostori Z; Maeda K; Eckhardt S; Bodrogi I
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):173-80. PubMed ID: 18214483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.